752 related articles for article (PubMed ID: 28289219)
1. Modulating IgG effector function by Fc glycan engineering.
Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
[TBL] [Abstract][Full Text] [Related]
2. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
3. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
4. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
Branstetter E; Duff RJ; Kuhns S; Padaki R
FEBS Open Bio; 2021 Nov; 11(11):2943-2949. PubMed ID: 34355537
[TBL] [Abstract][Full Text] [Related]
5. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Scallon BJ; Tam SH; McCarthy SG; Cai AN; Raju TS
Mol Immunol; 2007 Mar; 44(7):1524-34. PubMed ID: 17045339
[TBL] [Abstract][Full Text] [Related]
6. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
7. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
8. Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity.
Chen CL; Hsu JC; Lin CW; Wang CH; Tsai MH; Wu CY; Wong CH; Ma C
ACS Chem Biol; 2017 May; 12(5):1335-1345. PubMed ID: 28318221
[TBL] [Abstract][Full Text] [Related]
9. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
[TBL] [Abstract][Full Text] [Related]
10. An atomistic perspective on antibody-dependent cellular cytotoxicity quenching by core-fucosylation of IgG1 Fc N-glycans from enhanced sampling molecular dynamics.
Harbison A; Fadda E
Glycobiology; 2020 May; 30(6):407-414. PubMed ID: 31829411
[TBL] [Abstract][Full Text] [Related]
11. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
[TBL] [Abstract][Full Text] [Related]
12. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
[TBL] [Abstract][Full Text] [Related]
13. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
14. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
15. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
[TBL] [Abstract][Full Text] [Related]
16. Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.
Dekkers G; Treffers L; Plomp R; Bentlage AEH; de Boer M; Koeleman CAM; Lissenberg-Thunnissen SN; Visser R; Brouwer M; Mok JY; Matlung H; van den Berg TK; van Esch WJE; Kuijpers TW; Wouters D; Rispens T; Wuhrer M; Vidarsson G
Front Immunol; 2017; 8():877. PubMed ID: 28824618
[TBL] [Abstract][Full Text] [Related]
17. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
[TBL] [Abstract][Full Text] [Related]
18. Processing of complex N-glycans in IgG Fc-region is affected by core fucosylation.
Castilho A; Gruber C; Thader A; Oostenbrink C; Pechlaner M; Steinkellner H; Altmann F
MAbs; 2015; 7(5):863-70. PubMed ID: 26067753
[TBL] [Abstract][Full Text] [Related]
19. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies.
Yu X; Baruah K; Harvey DJ; Vasiljevic S; Alonzi DS; Song BD; Higgins MK; Bowden TA; Scanlan CN; Crispin M
J Am Chem Soc; 2013 Jul; 135(26):9723-32. PubMed ID: 23745692
[TBL] [Abstract][Full Text] [Related]
20. Engineering host cell lines to reduce terminal sialylation of secreted antibodies.
Naso MF; Tam SH; Scallon BJ; Raju TS
MAbs; 2010; 2(5):519-27. PubMed ID: 20716959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
